{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:29:31Z","timestamp":1790994571352,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Clozapine (CLZ) is used for treatment\u2010resistant schizophrenia. However, in Japanese patients, its pharmacokinetics are still not well described, and there are no case reports about drug interactions between CLZ and concomitant antiepileptics that can affect cytochrome P450 (CYP) activity, because CLZ is mainly metabolized by CYP. In two Japanese cases, for therapeutic drug monitoring, the trough plasma concentrations of CLZ,\n                    <jats:italic>N<\/jats:italic>\n                    \u2010desmethyl clozapine (NCLZ) and\n                    <jats:italic>N<\/jats:italic>\n                    \u2010oxide clozapine (OCLZ) were measured, and the ratios of them and the daily dose (D) were used as indicators of drug metabolism. In a male patient in his 20s, the CLZ\/D ratio ([ng\/mL]\/[mg\/day]) was significantly decreased, and both NCLZ\/CLZ and OCLZ\/CLZ ratios were significantly increased with carbamazepine, relative to CLZ alone. In another male patient in his 30s, the CLZ\/D ratio was lower with phenytoin than without phenytoin. The NCLZ\/CLZ ratio was higher with phenytoin than without phenytoin. Despite these expectations, the OCLZ\/CLZ ratio showed a slight decrease with phenytoin. These results in the two Japanese cases demonstrate the effects of antiepileptics on plasma concentrations, not only of CLZ but also of its major metabolites NCLZ and OCLZ. Metabolism\u2010enhancing interactions with CLZ were demonstrated for carbamazepine, a CYP3A4\u2010 and CYP1A2\u2010inducer. However, for phenytoin, which is also known as a CYP3A4\u2010inducer, the drug interactions with CLZ were not very clear due to the small limited data. These pharmacokinetic findings in only two cases must be confirmed by further investigations.\n                  <\/jats:p>","DOI":"10.1002\/npr2.70035","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:34:44Z","timestamp":1750912484000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Antiepileptic Drugs, Carbamazepine and Phenytoin, on Plasma Concentrations of Clozapine and Its\n                    <i>N<\/i>\n                    \u2010Desmethyl and\n                    <i>N<\/i>\n                    \u2010Oxide Metabolites in Japanese Patients With Schizophrenia"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9349-4067","authenticated-orcid":false,"given":"Kazuro","family":"Ikawa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacotherapy Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Imura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy Hiroshima University  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Sakata","sequence":"additional","affiliation":[{"name":"Nozoe Hills Hospital  Kurume Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Yasuzawa","sequence":"additional","affiliation":[{"name":"Nozoe Hills Hospital  Kurume Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Horikawa","sequence":"additional","affiliation":[{"name":"Nozoe Hills Hospital  Kurume Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S146114571100201X"},{"key":"e_1_2_12_3_1","unstructured":"Novartis Pharma K.K \u201cClozaril Tablets Package Insert \u201d (2024) https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/300242_1179049F1021_1_22."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.1.169a"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244881"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979584"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199408000-00006"},{"key":"e_1_2_12_8_1","first-page":"1","article-title":"Paralytic Ileus in a Patient on Clozapine Therapy Showing an Inverted Clozapine\/Norclozapine Ratio After Switching Valproic Acid to Carbamazepine: A Case Report","volume":"14","author":"Weringh G.","year":"2024","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"1","key":"e_1_2_12_9_1","first-page":"23","article-title":"Effect of Phenytoin on Plasma Clozapine Concentrations in Two Patients","volume":"52","author":"Miller D. D.","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(98)00202-3"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.04.014"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174694"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00822.x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010717"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2016.06.013"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00684.x"},{"key":"e_1_2_12_18_1","article-title":"Clozapine Therapy and CYP Genotype","author":"Pratt V. M.","year":"2021","journal-title":"Medical Genetics Summaries"},{"key":"e_1_2_12_19_1","unstructured":"Sun Pharma Japan Limited \u201cTegretol Tablets Package Insert \u201d (2024) https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/480866_1139002C1082_3_07."},{"key":"e_1_2_12_20_1","unstructured":"Sumitomo Pharma Co. Ltd \u201cAleviatin Tablets Package Insert \u201d (2024) https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/400093_1132002F1037_1_21."}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70035","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.70035","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.70035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:28:24Z","timestamp":1772994504000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.70035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/npr2.70035"],"URL":"https:\/\/doi.org\/10.1002\/npr2.70035","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"2025-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70035"}}